ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

IMAB I MAB

1.78
-0.03 (-1.66%)
May 10 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
I MAB IMAB NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
-0.03 -1.66% 1.78 19:00:00
Open Price Low Price High Price Close Price Previous Close
1.80 1.77 1.80 1.78 1.81
more quote information »

Recent News

Date Time Source Heading
4/30/202406:00PRNUSI-MAB Filed 2023 Annual Report on Form 20-F
4/05/202406:00PRNUSI-Mab to Participate at the 23rd Annual Needham Virtual..
4/02/202415:01PRNUSI-Mab Announces Closing of the Divestiture of Business..
3/14/202416:00PRNUSI-Mab Reports Full Year 2023 Financial Results and Business..
2/09/202415:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/08/202405:07EDGAR2Form 144 - Report of proposed sale of securities
2/07/202405:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/07/202405:00PRNUSI-Mab Signs Agreement to Divest its Assets and Business..
2/06/202419:55EDGAR2Form SCHEDULE 13G - Statement of acquisition of beneficial..
2/06/202405:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/05/202405:21EDGAR2Form 144 - Report of proposed sale of securities
1/02/202416:08DJNADRs Slump; FLJ Group Declines 21%
12/29/202305:12EDGAR2Form 144 - Report of proposed sale of securities
12/26/202305:22EDGAR2Form 144 - Report of proposed sale of securities
12/01/202313:41EDGAR2Form SC 13D - General statement of acquisition of beneficial..
11/16/202305:43EDGAR2Form 144 - Report of proposed sale of securities
11/06/202307:00PRNUSI-Mab Announces Participation at Jefferies and Piper..
11/02/202307:00PRNUSFelzartamab Granted Breakthrough Therapy Designation by U.S...
11/01/202307:00PRNUSI-Mab Announces Poster Presentations of 4-1BB Bispecific..
10/16/202307:00PRNUSI-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
10/10/202310:04EDGAR2Form 144 - Report of proposed sale of securities
10/10/202307:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/10/202307:00PRNUSI-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB..
9/29/202305:15EDGAR2Form 144 - Report of proposed sale of securities
9/22/202315:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
9/05/202307:00PRNUSI-Mab Announces Upcoming Participation at September..
8/17/202305:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
8/17/202305:00PRNUSI-Mab Provides Mid-Year 2023 Financial Results, Business and..
8/08/202307:00PRNUSI-Mab to Report Mid-Year 2023 Financial Results, Business..
7/11/202305:17EDGAR2Form 144 - Report of proposed sale of securities
7/05/202307:39EDGAR2Form 144 - Report of proposed sale of securities
7/05/202307:34EDGAR2Form 144 - Report of proposed sale of securities
7/05/202307:22EDGAR2Form 144 - Report of proposed sale of securities
7/05/202307:00PRNUSI-Mab Announces Publication of Claudin18.2 x 4-1BB..
6/22/202307:00PRNUSI-Mab Announces the Appointment of Raj Kannan as CEO
5/25/202316:01PRNUSI-Mab Announces Encouraging Phase 1b/2 Study Results of..